DOP2012000281A - Composiciones farmaceuticas y metodos para su elaboracion - Google Patents

Composiciones farmaceuticas y metodos para su elaboracion

Info

Publication number
DOP2012000281A
DOP2012000281A DO2012000281A DO2012000281A DOP2012000281A DO P2012000281 A DOP2012000281 A DO P2012000281A DO 2012000281 A DO2012000281 A DO 2012000281A DO 2012000281 A DO2012000281 A DO 2012000281A DO P2012000281 A DOP2012000281 A DO P2012000281A
Authority
DO
Dominican Republic
Prior art keywords
methods
pharmaceutical compositions
development
pazopanib
weight
Prior art date
Application number
DO2012000281A
Other languages
English (en)
Inventor
Manish K Gupta
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of DOP2012000281A publication Critical patent/DOP2012000281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas que incluyen una cantidad de una sal de adición de ácido de pazopanib equivalente a 10 miligramos/mililitro de pazopanib, y del 2 al 13 por ciento en peso/peso de una ciclodextrina modificada adecuada para utilizarse en una formulación oftálmica, así como métodos para la elaboración de las mismas.
DO2012000281A 2010-05-05 2012-11-02 Composiciones farmaceuticas y metodos para su elaboracion DOP2012000281A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05

Publications (1)

Publication Number Publication Date
DOP2012000281A true DOP2012000281A (es) 2013-05-31

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000281A DOP2012000281A (es) 2010-05-05 2012-11-02 Composiciones farmaceuticas y metodos para su elaboracion

Country Status (26)

Country Link
US (3) US20120028918A1 (es)
EP (1) EP2566331B1 (es)
JP (1) JP5835717B2 (es)
KR (1) KR20130071434A (es)
CN (1) CN102970871A (es)
AR (1) AR081364A1 (es)
AU (1) AU2011247995B2 (es)
BR (1) BR112012028291A2 (es)
CA (1) CA2798386A1 (es)
CL (1) CL2012003075A1 (es)
CO (1) CO6640262A2 (es)
CR (1) CR20120556A (es)
DO (1) DOP2012000281A (es)
EA (1) EA201291168A1 (es)
ES (1) ES2519615T3 (es)
HK (1) HK1175947A1 (es)
IL (1) IL222751A0 (es)
MA (1) MA34286B1 (es)
MX (1) MX2012012837A (es)
NZ (1) NZ603411A (es)
PE (1) PE20130217A1 (es)
SG (1) SG185087A1 (es)
TW (1) TW201206908A (es)
UY (1) UY33367A (es)
WO (1) WO2011140343A1 (es)
ZA (1) ZA201208265B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
PT2600930T (pt) 2010-08-05 2021-03-22 Forsight Vision4 Inc Aparelho injetor e método para distribuição de fármacos
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
CN104244952A (zh) * 2012-02-17 2014-12-24 药品循环公司 组蛋白脱乙酰酶抑制剂与帕唑帕尼的组合及其用途
CN110062479A (zh) * 2012-03-08 2019-07-26 三星电子株式会社 用于控制无线通信系统中的服务的方法
AU2014236455B2 (en) * 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2015031604A1 (en) 2013-08-28 2015-03-05 Crown Bioscience, Inc. Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CA2967330A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and methods of use
JP6818264B2 (ja) 2014-12-25 2021-01-20 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
CA3019822A1 (en) 2016-04-05 2017-10-12 Forsight Vision4, Inc. Implantable ocular drug delivery devices
CN110769853B (zh) * 2017-04-17 2022-06-03 北京生命科学研究所 治疗雄性衰老
WO2019028104A1 (en) * 2017-08-02 2019-02-07 Alphala Co., Ltd. NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP3810089B1 (en) * 2018-06-07 2023-08-02 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2895102A1 (en) * 2006-04-18 2007-11-01 Ekr Therapeutics, Inc. Pre-mixed, ready-to-use pharmaceutical compositions
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
EP2252616B1 (en) * 2008-01-30 2014-07-23 Genentech, Inc. Pyrazolopyrimidine pi3k inhibitor compounds and methods of use
CA2768237A1 (en) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same

Also Published As

Publication number Publication date
ZA201208265B (en) 2013-07-31
PE20130217A1 (es) 2013-03-21
EP2566331A1 (en) 2013-03-13
KR20130071434A (ko) 2013-06-28
CR20120556A (es) 2013-02-20
TW201206908A (en) 2012-02-16
EA201291168A1 (ru) 2013-06-28
UY33367A (es) 2011-10-31
EP2566331A4 (en) 2013-09-18
IL222751A0 (en) 2012-12-31
CN102970871A (zh) 2013-03-13
NZ603411A (en) 2014-10-31
MX2012012837A (es) 2013-01-24
MA34286B1 (fr) 2013-06-01
CO6640262A2 (es) 2013-03-22
AU2011247995B2 (en) 2014-07-31
US20150231265A1 (en) 2015-08-20
AR081364A1 (es) 2012-08-29
US20110281901A1 (en) 2011-11-17
CL2012003075A1 (es) 2013-03-08
US20120028918A1 (en) 2012-02-02
JP2013525501A (ja) 2013-06-20
SG185087A1 (en) 2012-12-28
WO2011140343A1 (en) 2011-11-10
BR112012028291A2 (pt) 2015-09-15
EP2566331B1 (en) 2014-09-03
HK1175947A1 (en) 2013-07-19
JP5835717B2 (ja) 2015-12-24
AU2011247995A1 (en) 2012-12-13
ES2519615T3 (es) 2014-11-07
CA2798386A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
DOP2012000281A (es) Composiciones farmaceuticas y metodos para su elaboracion
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
TR201905586T4 (tr) Amorf dapagli̇flozi̇n i̇çeren formülasyonlar
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
GT201200307A (es) NUEVOS DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3
CY1123456T1 (el) Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων
CR20120542A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
HN2010002518A (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
BR112012033755A2 (pt) composições e métodos antissépticos estáveis
BR112013000254A2 (pt) derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
ECSP13012667A (es) Compuestos de triazolopiridina
EA201590617A1 (ru) Композиции алкилированного циклодекстрина и способы их получения и применения
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112014027582A8 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
CL2013003588A1 (es) Composicion farmaceutica en forma de suspension oral que comprende como principio activo una fraccion de flavonoide y como excipiente goma de xantano en la cantidad de 0,30 %p/p a 0,60 %p/p; uso para el tratamiento de la insuficiencia venosa.
BR112013012719A2 (pt) "compostos como moduladores de receptor com utilidade terapêutica".
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
GT201300307A (es) "derivados de pirazol útiles como inhibidores de aldosterona sintasa"
BR112014010166A2 (pt) uso de uma composição para a fabricação de um produto para melhorar a pontuação na bateria de testes neuropsicológicos, método para avaliar a cognição de um indivíduo e uso de uma composição para a fabricação de um produto para tratar um indivíduo em necessidade da mesma
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
BR112014008588A2 (pt) derivados de 2-oxo-piperidinila